Get started
Author

Linda Josephine Christine van Waalwijk van Doorn

Observed names: L.L.C. van Waalwijk van Doorn, Linda J. C. van Waalwijk van Doorn, Linda J.C. van Waalwijk van Doorn, Linda van Waalwijk van Doorn, Waalwijk van Doorn, L.L.C. van
OpenAlex ID: A5022676293
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia
2015 · Willemijn J. Jansen, Rik Ossenkoppele, et al. · JAMA · 1,609
A Practical Guide to Immunoassay Method Validation
2015 · Ulf Andreasson, Armand Perret-Liaudet, et al. · Frontiers in Neurology · 544
PDF
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
2017 · Piotr Lewczuk, Peter Riederer, et al. · The World Journal of Biological Psychiatry · 307
PDF
Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia
2017 · Willemijn J. Jansen, Rik Ossenkoppele, et al. · JAMA Psychiatry · 140
PDF
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease
2018 · Niklas Mattsson, Colin Groot, et al. · Alzheimer s & Dementia · 88
Validation of soluble amyloid‐β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases
2016 · Linda J.C. van Waalwijk van Doorn, Marleen J. Koel‐Simmelink, et al. · Journal of Neurochemistry · 20
PDF
Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer’s Disease Cerebrospinal Fluid Biomarkers
2018 · Mafalda Ramos de Matos, Catarina Ferreira, et al. · Journal of Alzheimer s Disease · 17
PDF
Multicenter Analytical Validation of Aβ40 Immunoassays
2017 · Linda J. C. van Waalwijk van Doorn, Luka Kulic, et al. · Frontiers in Neurology · 13
PDF
Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer’s Disease Patients and Controls after Correction for Ventricular Volumes
2017 · Linda J.C. van Waalwijk van Doorn, Juan D. Gispert, et al. · Journal of Alzheimer s Disease · 12
White Matter Hyperintensities Are No Major Confounder for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers
2020 · Linda J.C. van Waalwijk van Doorn, Mohsen Ghafoorian, et al. · Journal of Alzheimer s Disease · 10
PDF
Cerebrospinal fluid biomarker assays for Alzheimer’s disease: standardization, validation and analysis of confounders
2020 · L.L.C. van Waalwijk van Doorn
Cerebrospinal fluid biomarker assays for Alzheimer’s disease: standardization, validation and analysis of confounders
2020 · Waalwijk van Doorn, L.L.C. van · Radboud Repository (Radboud University)
PDF
P1‐120: Standardization of a method for diagnostic biomarker validation for neurodegenerative diseases: App assays as example
2015 · Linda Josephine Christine van Waalwijk van Doorn, Marleen J. Koel-Simmelink, et al. · Alzheimer s & Dementia
P4‐229: Improved CSF‐based discrimination between Alzheimer's disease patients and controls after correction for ventricular volumes
2015 · Linda Josephine Christine van Waalwijk van Doorn, Juan D. Gispert, et al. · Alzheimer s & Dementia
PDF
JAMA Paper supplement
2015 · Willemijn J. Jansen, Rik Ossenkoppele, et al.
P4‐270: Correlations of Csf Biomarker Levels With Lateral Ventricular Csf Volumes
2014 · Linda Josephine Christine van Waalwijk van Doorn, Juan Domingo Gispert López, et al. · Alzheimer s & Dementia
Works count: 16
Citation count: 2,760
H-index: 10
I10-index: 10
Year
Topic
Type